GETI.B

189.6

+1.99%↑

VITR

158.3

+2.39%↑

EKTA.B

49.78

+0.32%↑

BIOAB

201

+0.5%↑

RAY.B

327.5

+1.55%↑

GETI.B

189.6

+1.99%↑

VITR

158.3

+2.39%↑

EKTA.B

49.78

+0.32%↑

BIOAB

201

+0.5%↑

RAY.B

327.5

+1.55%↑

GETI.B

189.6

+1.99%↑

VITR

158.3

+2.39%↑

EKTA.B

49.78

+0.32%↑

BIOAB

201

+0.5%↑

RAY.B

327.5

+1.55%↑

GETI.B

189.6

+1.99%↑

VITR

158.3

+2.39%↑

EKTA.B

49.78

+0.32%↑

BIOAB

201

+0.5%↑

RAY.B

327.5

+1.55%↑

GETI.B

189.6

+1.99%↑

VITR

158.3

+2.39%↑

EKTA.B

49.78

+0.32%↑

BIOAB

201

+0.5%↑

RAY.B

327.5

+1.55%↑

Search

Camurus AB

Закрыт

635.5 -0.55

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

635.5

Макс.

638

Ключевые показатели

By Trading Economics

Доход

31M

197M

Продажи

5.2M

558M

P/E

Средняя по отрасли

56.155

51.198

Прибыль на акцию

3.29

Рентабельность продаж

35.328

Сотрудники

265

EBITDA

21M

190M

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.4B

30B

Предыдущая цена открытия

636.05

Предыдущая цена закрытия

635.5

Camurus AB График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 июн. 2025 г., 14:31 UTC

Отчет

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 июн. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

6 июн. 2025 г., 20:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

6 июн. 2025 г., 20:33 UTC

Отчет

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 июн. 2025 г., 19:36 UTC

Обсуждения рынка

Oil Futures Post Solid Weekly Gains -- Market Talk

6 июн. 2025 г., 19:28 UTC

Обсуждения рынка

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 июн. 2025 г., 18:46 UTC

Обсуждения рынка

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 июн. 2025 г., 18:02 UTC

Обсуждения рынка

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 июн. 2025 г., 16:35 UTC

Отчет

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 июн. 2025 г., 16:34 UTC

Отчет

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 июн. 2025 г., 16:21 UTC

Обсуждения рынка

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 июн. 2025 г., 16:20 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

6 июн. 2025 г., 16:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

6 июн. 2025 г., 16:20 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

6 июн. 2025 г., 16:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

6 июн. 2025 г., 16:07 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

6 июн. 2025 г., 16:07 UTC

Обсуждения рынка

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 июн. 2025 г., 15:53 UTC

Обсуждения рынка

Mexican Inflation Seen Rising in May -- Market Talk

6 июн. 2025 г., 15:36 UTC

Обсуждения рынка

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 июн. 2025 г., 15:36 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

6 июн. 2025 г., 15:33 UTC

Обсуждения рынка

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 июн. 2025 г., 15:16 UTC

Обсуждения рынка

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 июн. 2025 г., 15:05 UTC

Обсуждения рынка

Silver at its Highest In Nearly 15 Years -- Market Talk

6 июн. 2025 г., 14:35 UTC

Обсуждения рынка

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 июн. 2025 г., 14:28 UTC

Обсуждения рынка

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 июн. 2025 г., 14:28 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

6 июн. 2025 г., 14:28 UTC

Обсуждения рынка

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 июн. 2025 г., 14:15 UTC

Обсуждения рынка

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 июн. 2025 г., 14:12 UTC

Отчет

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 июн. 2025 г., 14:09 UTC

Отчет

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Сравнение c конкурентами

Изменение цены

Camurus AB Прогноз

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.